Ophthalmic pharmaceutical company Tenpoint Therapeutics Ltd announced on Friday a New Drug Submission to Health Canada seeking approval of YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% for the treatment of presbyopia in adults.
The once-daily combination eye drop was approved by the US Food and Drug Administration (FDA) in January 2026 as the first and only dual-agent treatment of its kind for the condition.
The submission is supported by positive results from two Phase 3 clinical trials, BRIO I and BRIO II, in which YUVEZZI significantly improved near vision with once-daily administration. The treatment also demonstrated pupil constriction lasting from 30 minutes to 10 hours and was well tolerated, with no treatment-related serious adverse events reported across more than 72,000 dosing days monitored in BRIO II.
Presbyopia, the gradual loss of close-up vision that typically begins around age 45, affects approximately 2 billion people worldwide. The Canadian regulatory submission represents another step in Tenpoint's efforts to expand YUVEZZI's availability to patients globally.
Merck partners with Isomorphic Labs on AI-driven oncology drug discovery
Dicot Pharma secures EU approval to advance LIB-01 phase 2b study
NFL Biosciences enrolls first participant in Phase 2 smoking cessation trial
Anixa Biosciences and Curia to finalise formulation of breast cancer vaccine for Phase 2 trial
Akagera Medicines receives Gates Foundation grant expansion to advance tuberculosis vaccine
Ten63 Therapeutics launches BEYOND-Alpha early adopter programme
Eloxx Pharmaceuticals publishes Phase 2a exaluren data in nonsense mutation Alport syndrome
Bristol Myers Squibb reports first Phase 3 data for KarXT in Alzheimer's-related psychosis
Pfizer signs licensing agreement with Starna Therapeutics worth up to USD2.63bn
Inhibrx updates clinical data for ozekibart (INBRX-109) in Ewing sarcoma
Dicot Pharma initiates phase 2b clinical study of erectile dysfunction drug candidate
Sobi's Tryngolza for severe hypertriglyceridaemia receives EU approval
Oncoinvent reports favourable interim safety results for Radspherin in phase 2 ovarian cancer trial